Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Arena Pharmaceuticals, Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 320 staff and has a trailing 12-month revenue of around USD$4.6 million.
Since the stock market crash in March caused by coronavirus, Arena Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$66.15, which is 20.35% up on its pre-crash value of USD$52.69 and 100.76% up on the lowest point reached during the March crash when the shares fell as low as USD$32.95.
If you had bought USD$1,000 worth of Arena Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$842.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,394.44.
|Latest market close||USD$66.15|
|52-week range||USD$32.95 - USD$86.58|
|50-day moving average||USD$73.2974|
|200-day moving average||USD$62.7051|
|Wall St. target price||USD$93.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$10.836|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||2.04%|
|1 month (2020-10-30)||-22.83%|
|3 months (2020-08-28)||-6.01%|
|6 months (2020-05-29)||10.67%|
|1 year (2019-11-29)||39.62%|
|2 years (2018-11-29)||62.45%|
|3 years (2017-11-29)||117.31%|
|5 years (2015-11-27)||2,976.74%|
Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arena Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Arena Pharmaceuticals shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$549.8 million.
The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.6 million|
|Gross profit TTM||USD$574.9 million|
|Return on assets TTM||-17.42%|
|Return on equity TTM||-28.34%|
|Market capitalisation||USD$4.5 billion|
TTM: trailing 12 months
There are currently 3.6 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 2% down from 3.7 million last month.
There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.
Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 623867.5257732). Arena Pharmaceuticals's SIR currently stands at 5.82. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 5820 shares are currently held short.
However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.063% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.
Find out more about how you can short Arena Pharmaceuticals stock.
We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.
Arena Pharmaceuticals's shares were split on a 1:10 basis on 19 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.
Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $32.95 up to $86.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 1.1236. This would suggest that Arena Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.